Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
#3PRI RANKED
Most Cited Paper
in HIV Research and Treatment
18 Months Post-Publication
Class of 2026
“Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hiv-research-and-treatment/2026/
Topics
cabotegravir · rilpivirine · Long-acting injectable antiretroviral therapy · HIV viral suppression · Treatment switching · non-inferiority trial · Africa HIV cohort · Long-acting injectable antiretroviral therapy · Adherence · HIV viral suppression · Treatment switching · HIV viral suppression · HIV care in resource-limited settings
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited HIV Research and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/hiv-research-and-treatment/2026. Accessed 2026-07-21. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459